Fig. 4

Rapamycin promoted HASMC migration but did not abrogate the effects of METTL3 on HASMC migration and synthetic phenotype. A–B Transwell assay were used to assess the migratory capacity of HASMCs treated with DMSO or rapamycin (150 nM) for 24 h after METTL3 knockdown or not, and the cells were stained with crystal violet (n = 10). Scale bar: 100 μm. C–E The protein levels of contractile markers α-SMA and SM22α were evaluated by western blotting (C); D and E Quantitative results of blots in C (n = 4). β-actin serves as loading control. *p < 0.05 versus lenti-shRNA + DMSO